Novo Nordisk A/S (NYSE:NVO) Receives Average Rating of “Hold” from Brokerages

Novo Nordisk A/S (NYSE:NVO) has been given a consensus recommendation of “Hold” by the twenty-four research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nineteen have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $65.5625.

NVO has been the subject of several recent analyst reports. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. Finally, Kepler Capital Markets cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors and hedge funds have recently modified their holdings of the business. True Wealth Design LLC lifted its holdings in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S during the third quarter valued at $25,000. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S in the 4th quarter worth about $25,000. WealthCollab LLC raised its position in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the last quarter. Finally, American National Bank & Trust purchased a new position in Novo Nordisk A/S in the 4th quarter worth about $28,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $36.92 on Friday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $164.86 billion, a P/E ratio of 10.64, a PEG ratio of 8.63 and a beta of 0.73. The stock’s 50 day moving average is $43.93 and its 200 day moving average is $49.98.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is 50.43%.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.K. drug regulator NICE recommended Wegovy for heart‑disease prevention, expanding NHS access by about 1.2 million people — a material commercial win that supports longer‑term demand for Wegovy. Novo Nordisk shares rise after Wegovy recommended by Britain’s drug price regulator
• Positive Sentiment: Management launched a Wegovy subscription pricing model and expanded telehealth partnerships to lower out‑of‑pocket costs and improve adherence — a tactical move to protect market share and pricing power in self‑pay segments. NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
• Positive Sentiment: Novo released a cross‑trial comparison (ORION) showing oral Wegovy produced greater mean weight loss and fewer dropouts versus Lilly’s pill — messaging aimed at bluntly defending the oral franchise as Lilly begins commercialization. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Pipeline progress continues: Novo is advancing next‑generation metabolic candidates (including a triple‑agonist program) through early clinical trials, which supports longer‑term upside beyond current GLP‑1 competition. Novo Nordisk Triple Agonist Progress Spurs Questions On Valuation Gap
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — signaling analysts see limited near‑term upside while acknowledging the Wegovy pill momentum. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market coverage notes the shares edged higher and held up early despite Lilly’s approval — suggesting investors had partially priced in competitive pressure. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: FDA approval of Eli Lilly’s oral GLP‑1 (Foundayo/orforglipron) and an expected multi‑billion dollar commercial debut create direct pricing and market‑share pressure on Novo’s Wegovy/Ozempic franchises. Analysts and traders are pricing a more contested oral market going forward. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Broader policy/regulatory risk: reports the administration is considering tariffs of up to 100% on branded drug imports could create volatility and uncertainty for multinational drugmakers if no concessions/deals are struck. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Analyst commentary highlights intensifying duopoly dynamics with Eli Lilly, product gaps in injectables vs. Lilly, and patent/competitive lifecycle concerns — risks that could pressure growth and valuation if market share slips. Novo Nordisk: Competing In A Duopoly

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.